OTCPK:OSSF.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. More Details


Snowflake Analysis

Moderate growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Össur hf's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OSSF.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

OSSF.F

0.6%

US Medical Equipment

1.3%

US Market


1 Year Return

-9.3%

OSSF.F

17.1%

US Medical Equipment

15.8%

US Market

Return vs Industry: OSSF.F underperformed the US Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: OSSF.F underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

OSSF.FIndustryMarket
7 Day0%0.6%1.3%
30 Day0%-2.4%-4.1%
90 Day-0.7%10.6%8.4%
1 Year-9.3%-9.3%18.1%17.1%18.4%15.8%
3 Year55.7%55.7%70.9%66.5%38.2%29.0%
5 Yearn/a144.0%125.3%84.9%64.0%

Price Volatility Vs. Market

How volatile is Össur hf's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Össur hf undervalued compared to its fair value and its price relative to the market?

164.39x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: OSSF.F ($6.85) is trading above our estimate of fair value ($3.36)

Significantly Below Fair Value: OSSF.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OSSF.F is poor value based on its PE Ratio (164.4x) compared to the US Medical Equipment industry average (49.6x).

PE vs Market: OSSF.F is poor value based on its PE Ratio (164.4x) compared to the US market (18x).


Price to Earnings Growth Ratio

PEG Ratio: OSSF.F is poor value based on its PEG Ratio (3.9x)


Price to Book Ratio

PB vs Industry: OSSF.F is overvalued based on its PB Ratio (5.7x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Össur hf forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

42.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSSF.F's forecast earnings growth (42.2% per year) is above the savings rate (2.2%).

Earnings vs Market: OSSF.F's earnings (42.2% per year) are forecast to grow faster than the US market (22.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OSSF.F's revenue (7% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: OSSF.F's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OSSF.F's Return on Equity is forecast to be low in 3 years time (13.3%).


Next Steps

Past Performance

How has Össur hf performed over the past 5 years?

5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSSF.F has a large one-off loss of $25.5M impacting its June 30 2020 financial results.

Growing Profit Margin: OSSF.F's current net profit margins (3%) are lower than last year (13%).


Past Earnings Growth Analysis

Earnings Trend: OSSF.F's earnings have grown by 5.3% per year over the past 5 years.

Accelerating Growth: OSSF.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: OSSF.F had negative earnings growth (-77.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.8%).


Return on Equity

High ROE: OSSF.F's Return on Equity (4%) is considered low.


Next Steps

Financial Health

How is Össur hf's financial position?


Financial Position Analysis

Short Term Liabilities: OSSF.F's short term assets ($393.0M) exceed its short term liabilities ($149.4M).

Long Term Liabilities: OSSF.F's short term assets ($393.0M) do not cover its long term liabilities ($496.5M).


Debt to Equity History and Analysis

Debt Level: OSSF.F's debt to equity ratio (69.6%) is considered high.

Reducing Debt: OSSF.F's debt to equity ratio has increased from 24.9% to 69.6% over the past 5 years.

Debt Coverage: OSSF.F's debt is well covered by operating cash flow (29.3%).

Interest Coverage: OSSF.F's interest payments on its debt are well covered by EBIT (8.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Össur hf current dividend yield, its reliability and sustainability?

0.30%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: OSSF.F's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.71%).

High Dividend: OSSF.F's dividend (0.3%) is low compared to the top 25% of dividend payers in the US market (4.83%).


Stability and Growth of Payments

Stable Dividend: OSSF.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: OSSF.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: OSSF.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSSF.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Jón Sigurdsson (64 yo)

24.67yrs

Tenure

US$1,694,000

Compensation

Mr. Jón Sigurdsson has been the Chief Executive Officer and President of Gibaud SAS since 1996. Mr. Sigurdsson has been Senior Vice President of Procurement at Promens Canada Inc. and Promens hf. since Jul ...


CEO Compensation Analysis

Compensation vs Market: Jón's total compensation ($USD1.69M) is below average for companies of similar size in the US market ($USD5.74M).

Compensation vs Earnings: Jón's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jón Sigurdsson
CEO & President24.67yrsUS$1.69m0.12%
$ 3.8m
Ossur Kristinsson
no dataUS$25.00kno data
Sveinn Sölvason
Chief Financial Officer7.33yrsUS$221.00k0.0059%
$ 178.6k
Egill Jónsson
Executive Vice President of Manufacturing & Operationsno dataUS$444.00k0.20%
$ 5.9m
David Hreidarsson
Investor Relations Managerno datano datano data
Sigurborg Arnarsdottir
Compliance Officer18.67yrsno datano data
Ólafur Gylfason
Executive Vice President of Sales & Marketing4.5yrsUS$600.00k0.0023%
$ 68.1k
Margrét Friðriksdóttir
Executive Vice President of Human Resources & Corporate Strategyno dataUS$242.00k0.0039%
$ 116.5k
Gudjon Karason
Executive Vice President of Clinics2.83yrsno data0.010%
$ 305.4k
Kristleifur Kristjansson
Executive Vice President of Research & Development0.75yrno data0.00044%
$ 13.3k
Thorvaldur Ingvarsson
Consultant2.83yrsUS$422.00kno data

4.5yrs

Average Tenure

60yo

Average Age

Experienced Management: OSSF.F's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Niels Jacobsen
Chairman of the Board14.67yrsUS$97.00k0.048%
$ 1.5m
Kristján Ragnarsson
Vice Chairman8.5yrsUS$58.00kno data
Svafa Grönfeldt
Independent Director12.67yrsUS$39.00kno data
Guðbjörg Eggertsdóttir
Independent Director7.5yrsUS$39.00k0.0062%
$ 187.9k
Arne Nielsen
Director11.67yrsUS$39.00kno data

11.7yrs

Average Tenure

63yo

Average Age

Experienced Board: OSSF.F's board of directors are seasoned and experienced ( 11.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Össur hf.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Össur hf.
  • Ticker: OSSF.F
  • Exchange: OTCPK
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr.19.102b
  • Listing Market Cap: kr.3.011b
  • Shares outstanding: 421.67m
  • Website: https://www.ossur.com

Number of Employees


Location

  • Össur hf.
  • Grjothals 1-5
  • Reykjavik
  • 110
  • Iceland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
0FIWLSE (London Stock Exchange)YesCommon StockGBDKKOct 1999
OSSRCPSE (OMX Nordic Exchange Copenhagen)YesCommon StockDKDKKOct 1999
OSSRCBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBDKKOct 1999
OSSF.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 1999
OSSU.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDDec 2011

Biography

Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. The company’s pros ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/30 00:10
End of Day Share Price2020/08/14 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.